Current Status of Familial LCAT Deficiency in Japan-Reference-Cited by-同舟云学术

Current Status of Familial LCAT Deficiency in Japan

Published:2021 Issue: Volume: Page:
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Kuroda Masayuki¹,Bujo Hideaki²,Yokote Koutaro³,Murano Takeyoshi⁴,Yamaguchi Takashi⁵,Ogura Masatsune⁶,Ikewaki Katsunori⁷,Koseki Masahiro⁸,Takeuchi Yasuo⁹,Nakatsuka Atsuko¹⁰,Hori Mika¹¹,Matsuki Kota¹²,Miida Takashi¹³,Yokoyama Shinji¹⁴,Wada Jun¹⁰,Harada-Shiba Mariko¹⁵,

Affiliation:

1. Center for Advanced Medicine, Chiba University Hospital, Chiba University

2. Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center

3. Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine

4. Clinical Laboratory Program, Faculty of Science, Toho University

5. Center of Diabetes, Endocrinology and Metabolism, Toho University Sakura Medical Center

6. Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute

7. Division of Neurology, Anti-Aging, and Vascular Medicine, Department of Internal Medicine, National Defense Medical College

8. Division of Cardiovascular Medicine, Department of Medicine, Osaka University Graduate School of Medicine

9. Division of Nephrology, Kitasato University School of Medicine

10. Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

11. Department of Endocrinology, Research Institute of Environmental Medicine, Nagoya University

12. Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine

13. Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine

14. Institute for Biological Functions, Chubu University

15. Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center Research Institute

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_RV17051/_pdf

Reference67 articles.

1. 1) Glomset JA, Parker F, Tjaden M, Williams RH. The esterification in vitro of free cholesterol in human and rat plasma. Biochim Biophys Acta, 1962; 58: 398-406

2. 2) Glomset JA, Janssen ET, Kennedy R, Dobbins J. Role of plasma lecithin: cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res, 1966; 7: 638-648

3. 3) Carlson LA., Philipson B. Fish-eye disease: a new familial condition with massive corneal opacities and dyslipoproteinem. Lancet, 1979; 314: 921-924

4. 4) Glomset JA, Assmann G, Gjone E, Norum KR. Lecithin cholesterol acyltransferase deficiency and fish eye disease. In: The Metabolic and Molecular Bases of Inherited Disease, 7th ed. by Scriver CR, Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngaarden JB, Fredrickson DS., McGraw-Hill Inc., New York, 1995, 1933-1951

5. 5) Santamarina-Fojo S, Hoeg JM, Assman G, Brewer Jr HB. Lecithin cholesterol acyltransferase deficiency and fish eye disease. In: The metabolic and molecular bases of inherited disease, 8th ed. by Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B., McGraw-Hill Inc., New York, 2001, 2817-2833

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Symptomatic Lecithin-Cholesterol Acyltransferase Gene Mutation With Corneal Amyloidosis;Cornea;2024-08-22

2. Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions;Pharmaceuticals;2024-08-15

3. Transitional Medicine of Intractable Primary Dyslipidemias in Japan;Journal of Atherosclerosis and Thrombosis;2024-05-01

4. Familial LCAT Deficiency and Low HDL-C Levels: In silico Characterization of Two Rare LCAT Missense Mutations;The Application of Clinical Genetics;2024-02

5. LCAT-trial-24 weeks: Protocol for a clinical study to evaluate the safety of regenerative medicine and gene therapy by the autologous transplantation of human lecithin:cholesterol acyltransferase gene-transduced human pre-adipocytes;Contemporary Clinical Trials Communications;2022-08